Bladder Cancer Funding Analyzer launched on bladder cancer website

February 16, 2017

Amsterdam, NL, February 16, 2017 - Bladder Cancer (BLC) is proud to announce the launch of the Bladder Cancer Funding Analyzer (BCFA) on the BLC website. It is a free service that is part of a new suite of online features that have been designed to serve the needs of the bladder cancer research community.

BCFA presents in-depth data on more than fifty funders from over twenty countries including the United States, all of the European Union, the United Kingdom, Canada and Japan. It allows users to easily locate funding related to bladder cancer and analyze funding streams and trends. Further, it facilitates a better understanding of research organizations' funding portfolios and the funding patterns of specific funders, both of which are critical when developing grant applications.

"This is a unique and remarkable tool that will be very valuable to everyone doing bladder cancer research," explained BLC's Editors-in-Chief Seth P. Lerner, MD, and Dan Theodorescu, MD, PhD. "It is becoming increasingly important to know more about the funding landscape and about who is working on what project so effective collaborations can be sought out."

Built by ÜberResearch, a solutions and services company focused on the needs of science funders, BCFA includes all funding related to bladder cancer drawn from ÜberResearch's extensive grant database of more than $1.1 trillion of funded research, representing over 3.4 million projects from 258 different funders like the National Institutes of Health and the National Science Foundation in the U.S. and the Wellcome Trust and U.K. Research Councils in the U.K.

Users can conduct line-of-investigation queries (e.g., epithelial-mesenchymal transition, gemcitabine-cisplatin therapy, urinary diversion) to look for funding trends and to see which investigators in which countries have been the most successful in obtaining funding in a given area of bladder cancer research. New funding information will be added to BCFA on an ongoing basis.

"We invite all bladder cancer researchers to access this valuable service at http://www.bladdercancerjournal.com/funding, which we are pleased to make available at no charge," added Dr. Lerner and Dr. Theodorescu.
-end-


IOS Press

Related Bladder Cancer Articles from Brightsurf:

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer.

Anthrax may be the next tool in the fight against bladder cancer
Researchers at Purdue University have come up with a way to combine the anthrax toxin with a growth factor to kill bladder cancer cells and tumors.

Effectiveness of a new bladder cancer treatment demonstrated
Demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment.

Lifting the lid on bladder cancer support
Bladder cancer is a painful and sometimes life-threatening condition that patients can find difficult to talk about, with many becoming homebound as they cope with debilitating side effects such as incontinence.

How genomics profiling can help identify the best treatment for bladder cancer
A new computational tool -- a single-patient classifier -- effectively enables physicians to assign a bladder cancer subtype to an individual patient's cancer using that patient's genomic data.

Early menopause in smokers linked to bladder cancer
Research shows that experiencing menopause before the age of 45 is associated with a higher risk of bladder cancer.

Olfactory receptor as therapeutic target in bladder cancer
Researchers from Bochum have detected an olfactory receptor in the human bladder that might prove useful for bladder cancer therapy and diagnosis.

Bladder cancer model could pave the way for better drug efficacy studies
In the journal Cancer Research, UNC Lineberger Comprehensive Cancer Center researchers report they have developed a model of luminal bladder cancer, one of the two subtypes of advanced bladder cancer.

Genetic fixer-uppers may help predict bladder cancer prognosis
Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers, who found that bladder cancer patients who had mutations in their ATM or RB1 genes -- proteins that help repair DNA damage when they're functioning normally -- tended not to live as long as patients without the mutations.

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer
Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumors have certain genetic mutations may respond particularly well to this combination approach, according to the results of a clinical trial published in European Urology.

Read More: Bladder Cancer News and Bladder Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.